Buprenorphine on Board: Abetting Medication-Assisted Treatment


Buprenorphine is an evidence-based therapy that can be applied in medication-assisted treatment (MAT) for opioid use disorder (OUD). Still, barriers stand in the way of patient access. Join us for this in-depth overview of buprenorphine for MAT and the benefits of pharmacists dispensing naloxone. Learn what you can do to expand access to buprenorphine for MAT—along with the appropriate language to use with patients to avoid sounding judgmental.  

Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. Describe the differences between buprenorphine products for MAT and those for pain. 
  2. Discuss the impact of pharmacist-driven MAT dispensing.
  3. Identify barriers to pharmacist dispensing and patient access to buprenorphine for MAT and effective strategies in overcoming those barriers. 
  4. Describe appropriate terminology to reduce stigma when discussing MAT with a patient. 
  5. Use evidence-based communication strategies to engage patients about MAT.  
  6. Discuss effective approaches for physicians and community pharmacists to collaborate. 

Technician Learning Objectives

Jake Nichols, Pharm.D., MBA
Director of Clinical Strategy
Axial Healthcare
Michael Frost, MD, FACP, FASAM
President/Medical Director
The Frost Medical Group LLC
Learning Level: Level 2
Track: Community-Based Pharmacy Practice, Pharmacist Clinical Patient Care Services
Session Time Slot(s): 
Friday, March 20
3:30 PM - 5:00 PM
Gaylord National Resort - National Harbor 4-5
ACPE Pharmacist: 0202-0000-20-015-L08-P
CEUs Pharmacist: 0.15
Activity Type: